Free Trial

Celldex Therapeutics 8/8/2024 Earnings Report

Celldex Therapeutics logo
$26.04 -0.16 (-0.61%)
(As of 05:26 PM ET)

Celldex Therapeutics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$2.50 million
Expected Revenue
$1.13 million
Beat/Miss
Beat by +$1.37 million
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Time
After Market Closes
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Celldex Therapeutics Earnings Headlines

Celldex announces first patient dosed in Phase 1a study of CDX-622
Is the Trump/Musk duo good for shares of TSLA?
If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.
Celldex Therapeutics Reports Q3 2024 Progress and Financials
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings